Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
1.
Virology ; 554: 1-8, 2021 02.
Article de Anglais | MEDLINE | ID: mdl-33316731

RÉSUMÉ

Identification of viral immune escape mutations that compromise HIV's ability to replicate may aid rational attenuation-based vaccine design. Previously we reported amino acids associated with altered viral replication capacity (RC) from a sequence-function analysis of 487 patient-derived RT-integrase sequences. In this study, site-directed mutagenesis experiments were performed to validate the effect of these mutations on RC. Viral reverse transcripts were measured by quantitative PCR and structural modelling was performed to gain further insight into the effect of reverse transcriptase (RT) mutations on reverse transcription. RT-integrase variants in or flanking cytotoxic T cell epitopes in the RT palm (158S), RT thumb (241I and 257V) and integrase catalytic core domain (124N) were confirmed to significantly reduce RC. RT mutants showed a delayed initiation of viral DNA synthesis. Structural models provide insight into how these attenuating RT mutations may affect amino acid interactions in the helix clamp, primer grip and catalytic site regions.


Sujet(s)
Vaccins contre le SIDA , Intégrase du VIH/génétique , Intégrase du VIH/métabolisme , Transcriptase inverse du VIH/génétique , Transcriptase inverse du VIH/métabolisme , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/génétique , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/physiologie , Domaine catalytique , Lignée cellulaire , Déterminants antigéniques des lymphocytes T/immunologie , Gènes pol , Intégrase du VIH/composition chimique , Intégrase du VIH/immunologie , Transcriptase inverse du VIH/composition chimique , Transcriptase inverse du VIH/immunologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/enzymologie , Humains , Modèles moléculaires , Mutagenèse dirigée , Mutation , Conformation des protéines , Réaction de polymérisation en chaine en temps réel , Transcription inverse , Lymphocytes T cytotoxiques/immunologie , Développement de vaccin , Vaccins atténués , Réplication virale
2.
BMC Med ; 18(1): 81, 2020 03 25.
Article de Anglais | MEDLINE | ID: mdl-32209092

RÉSUMÉ

INTRODUCTION: Immunological damage in acute HIV infection (AHI) may predispose to detrimental clinical sequela. However, studies on the earliest HIV-induced immunological changes are limited, particularly in sub-Saharan Africa. We assessed the plasma cytokines kinetics, and their associations with virological and immunological parameters, in a well-characterized AHI cohort where participants were diagnosed before peak viremia. METHODS: Blood cytokine levels were measured using Luminex and ELISA assays pre-infection, during the hyperacute infection phase (before or at peak viremia, 1-11 days after the first detection of viremia), after peak viremia (24-32 days), and during the early chronic phase (77-263 days). Gag-protease-driven replicative capacities of the transmitted/founder viruses were determined using a green fluorescent reporter T cell assay. Complete blood counts were determined before and immediately following AHI detection before ART initiation. RESULTS: Untreated AHI was associated with a cytokine storm of 12 out of the 33 cytokines analyzed. Initiation of ART during Fiebig stages I-II abrogated the cytokine storm. In untreated AHI, virus replicative capacity correlated positively with IP-10 (rho = 0.84, P < 0.001) and IFN-alpha (rho = 0.59, P = 0.045) and inversely with nadir CD4+ T cell counts (rho = - 0.58, P = 0.048). Hyperacute HIV infection before the initiation of ART was associated with a transient increase in monocytes (P < 0.001), decreased lymphocytes (P = 0.011) and eosinophils (P = 0.003) at Fiebig stages I-II, and decreased eosinophils (P < 0.001) and basophils (P = 0.007) at Fiebig stages III-V. Levels of CXCL13 during the untreated hyperacute phase correlated inversely with blood eosinophils (rho = - 0.89, P < 0.001), basophils (rho = - 0.87, P = 0.001) and lymphocytes (rho = - 0.81, P = 0.005), suggesting their trafficking into tissues. In early treated individuals, time to viral load suppression correlated positively with plasma CXCL13 at the early chronic phase (rho = 0.83, P = 0.042). CONCLUSION: While commencement of ART during Fiebig stages I-II of AHI abrogated the HIV-induced cytokine storm, significant depletions of eosinophils, basophils, and lymphocytes, as well as transient expansions of monocytes, were still observed in these individuals in the hyperacute phase before the initiation of ART, suggesting that even ART initiated during the onset of viremia does not abrogate all HIV-induced immune changes.


Sujet(s)
Cytokines/usage thérapeutique , Infections à VIH/immunologie , Charge virale/méthodes , Virémie/immunologie , Adolescent , Adulte , Cytokines/pharmacologie , Femelle , Infections à VIH/traitement médicamenteux , Humains , Mâle , Jeune adulte
4.
J Virol ; 92(19)2018 10 01.
Article de Anglais | MEDLINE | ID: mdl-29997209

RÉSUMÉ

CD8+ T cell-mediated escape mutations in Gag can reduce HIV-1 replication capacity (RC) and alter disease progression, but less is known about immune-mediated attenuation in other HIV-1 proteins. We generated 487 recombinant viruses encoding RT-integrase from individuals with chronic (n = 406) and recent (n = 81) HIV-1 subtype C infection and measured their in vitro RC using a green fluorescent protein (GFP) reporter T cell assay. In recently infected individuals, reverse transcriptase (RT)-integrase-driven RC correlated significantly with viral load set point (r = 0.25; P = 0.03) and CD4+ T cell decline (P = 0.013). Moreover, significant associations between RT integrase-driven RC and viral load (r = 0.28; P < 0.0001) and CD4+ T cell count (r = -0.29; P < 0.0001) remained in chronic infection. In early HIV infection, host expression of the protective HLA-B*81 allele was associated with lower RC (P = 0.05), as was expression of HLA-B*07 (P = 0.02), suggesting early immune-driven attenuation of RT-integrase by these alleles. In chronic infection, HLA-A*30:09 (in linkage disequilibrium with HLA-B*81) was significantly associated with lower RC (P = 0.05), and all 6 HLA-B alleles with the lowest RC measurements represented protective alleles, consistent with long-term effects of host immune pressures on lowering RT-integrase RC. The polymorphisms V241I, I257V, P272K, and E297K in reverse transcriptase and I201V in integrase, all relatively uncommon polymorphisms occurring in or adjacent to optimally described HLA-restricted cytotoxic T-lymphocyte epitopes, were associated with reduced RC. Together, our data suggest that RT-integrase-driven RC is clinically relevant and provide evidence that immune-driven selection of mutations in RT-integrase can compromise RC.IMPORTANCE Identification of viral mutations that compromise HIV's ability to replicate may aid rational vaccine design. However, while certain escape mutations in Gag have been shown to reduce HIV replication and influence clinical progression, less is known about the consequences of mutations that naturally arise in other HIV proteins. Pol is a highly conserved protein, but the impact of Pol function on HIV disease progression is not well defined. Here, we generated recombinant viruses using the RT-integrase region of Pol derived from HIV-1C-infected individuals with recent and chronic infection and measured their ability to replicate in vitro We demonstrate that RT-integrase-driven replication ability significantly impacts HIV disease progression. We further show evidence of immune-mediated attenuation in RT-integrase and identify specific polymorphisms in RT-integrase that significantly decrease HIV-1 replication ability, suggesting which Pol epitopes could be explored in vaccine development.


Sujet(s)
Infections à VIH/génétique , Intégrase du VIH/génétique , Transcriptase inverse du VIH/génétique , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/génétique , Interactions hôte-pathogène , Produits du gène gag du virus de l'immunodéficience humaine/génétique , Allèles , Numération des lymphocytes CD4 , Lymphocytes T CD4+/immunologie , Lymphocytes T CD4+/virologie , Lymphocytes T CD8+/immunologie , Lymphocytes T CD8+/virologie , Études de cohortes , Évolution de la maladie , Déterminants antigéniques des lymphocytes T/génétique , Déterminants antigéniques des lymphocytes T/immunologie , Régulation de l'expression des gènes , Gènes rapporteurs , Génotype , Protéines à fluorescence verte/génétique , Protéines à fluorescence verte/immunologie , Infections à VIH/immunologie , Infections à VIH/virologie , Intégrase du VIH/immunologie , Transcriptase inverse du VIH/immunologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/classification , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/immunologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/pathogénicité , Antigènes HLA-A/génétique , Antigènes HLA-A/immunologie , Antigènes HLA-B/génétique , Antigènes HLA-B/immunologie , Humains , Déséquilibre de liaison , Polymorphisme de nucléotide simple , Transduction du signal , Charge virale , Réplication virale , Produits du gène gag du virus de l'immunodéficience humaine/immunologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...